Terms: = Ovarian cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Prognosis
1449 results:
1. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive profiling of endocrine metabolism identifies a novel signature with robust predictive value in ovarian cancer.
Yu D; Luo Y; Guo R; Ma F; Chang Y; Dang J
J Gene Med; 2024 May; 26(5):e3686. PubMed ID: 38689382
[TBL] [Abstract] [Full Text] [Related]
3. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract] [Full Text] [Related]
4. Germ cell-specific gene 2 accelerates cell cycle in epithelial ovarian cancer by inhibiting GSK3α-p27 cascade.
Zhu K; Ma X; Guan X; Tong Y; Xie S; Wang Y; Zheng H; Guo L; Lu R
J Mol Histol; 2024 Jun; 55(3):241-251. PubMed ID: 38613588
[TBL] [Abstract] [Full Text] [Related]
5. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous ovarian cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract] [Full Text] [Related]
6. The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
Wei Y; Chen Z; Li Y; Song K
Oncogene; 2024 May; 43(20):1565-1578. PubMed ID: 38561505
[TBL] [Abstract] [Full Text] [Related]
7. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
8. RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter.
Wu H; Xia L; Sun L; Li D; Liu X; Song H; Sheng J; Wang K; Feng Q
J Cell Mol Med; 2024 Mar; 28(6):e18115. PubMed ID: 38436544
[TBL] [Abstract] [Full Text] [Related]
9. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
11. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C
Front Immunol; 2024; 15():1346686. PubMed ID: 38333210
[TBL] [Abstract] [Full Text] [Related]
12. EZH2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
13. CircRNA
Xing T; Chen J; Ding J; Liu J; Ling S; Luo Y
Discov Med; 2024 Jan; 36(180):113-120. PubMed ID: 38273751
[TBL] [Abstract] [Full Text] [Related]
14. LRP8 promotes tumorigenesis in ovarian cancer through inhibiting p53 signaling.
Xu Y; Zhou Y; Yi X; Nie X
Cell Biol Int; 2024 May; 48(5):626-637. PubMed ID: 38263609
[TBL] [Abstract] [Full Text] [Related]
15. CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer.
Shao D; Zhou H; Yu H; Zhu X
Medicine (Baltimore); 2024 Jan; 103(3):e36891. PubMed ID: 38241595
[TBL] [Abstract] [Full Text] [Related]
16. Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol.
Hayes SC; Spence RR; Janda M; Eakin E; Shannon C; Goh J; Beesley VL; Vagenas D; Webb P; Coward J; Gordon LG; O'Neill H; Williams M; Rye S; Newton MJ; Baniahmadi S; Nascimento M; Nicklin J; Garret A; Obermair A
BMJ Open; 2024 Jan; 14(1):e077158. PubMed ID: 38238061
[TBL] [Abstract] [Full Text] [Related]
17. Mini review of photoacoustic clinical imaging: a noninvasive tool for disease diagnosis and treatment evaluation.
Liu H; Wang M; Ji F; Jiang Y; Yang M
J Biomed Opt; 2024 Jan; 29(Suppl 1):S11522. PubMed ID: 38230369
[TBL] [Abstract] [Full Text] [Related]
18. MARCH5-mediated downregulation of ACC2 promotes fatty acid oxidation and tumor progression in ovarian cancer.
Zhao S; Wang Q; Zhang X; Ma B; Shi Y; Yin Y; Kong W; Zhang W; Li J; Yang H
Free Radic Biol Med; 2024 Feb; 212():464-476. PubMed ID: 38211832
[TBL] [Abstract] [Full Text] [Related]
19. ovarian cancer cells regulate their mitochondrial content and high mitochondrial content is associated with a poor prognosis.
Weigelt J; Petrosyan M; Oliveira-Ferrer L; Schmalfeldt B; Bartmann C; Dietl J; Stürken C; Schumacher U
BMC Cancer; 2024 Jan; 24(1):43. PubMed ID: 38191325
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract] [Full Text] [Related]
[Next]
